{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:49:21Z","timestamp":1793321361762,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T00:00:00Z","timestamp":1528416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T00:00:00Z","timestamp":1528416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009794","name":"Breast Cancer Now","doi-asserted-by":"publisher","award":["CTR-Q3"],"award-info":[{"award-number":["CTR-Q3"]}],"id":[{"id":"10.13039\/100009794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009794","name":"Breast Cancer Now","doi-asserted-by":"publisher","award":["CTR-Q3"],"award-info":[{"award-number":["CTR-Q3"]}],"id":[{"id":"10.13039\/100009794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019402","name":"Puma Biotechnology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019402","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000981","name":"Arthur Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000981","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000981","name":"Arthur Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000981","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012139","name":"Royal Marsden NHS Foundation Trust","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012139","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100012139","name":"Royal Marsden NHS Foundation Trust","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012139","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Endocrine therapies are the mainstay of treatment for oestrogen receptor (ER)-positive (ER<jats:sup>+<\/jats:sup>) breast cancer (BC). However, resistance remains problematic largely due to enhanced cross-talk between ER and growth factor pathways, circumventing the need for steroid hormones. Previously, we reported the anti-proliferative effect of everolimus (RAD001-mTORC1 inhibitor) with endocrine therapy in resistance models; however, potential routes of escape from treatment via ERBB2\/3 signalling were observed. We hypothesised that combined targeting of three cellular nodes (ER, ERBB, and mTORC1) may provide enhanced long-term clinical utility.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A panel of ER<jats:sup>+<\/jats:sup> BC cell lines adapted to long-term oestrogen deprivation (LTED) and expressing <jats:italic>ESR1<\/jats:italic>\n              <jats:sup>\n                <jats:italic>wt<\/jats:italic>\n              <\/jats:sup> or <jats:italic>ESR1<\/jats:italic>\n              <jats:sup>\n                <jats:italic>Y537S<\/jats:italic>\n              <\/jats:sup>, modelling acquired resistance to an aromatase-inhibitor (AI), were treated in vitro with a combination of RAD001 and neratinib (pan-ERBB inhibitor) in the presence or absence of oestradiol (E2), tamoxifen (4-OHT), or fulvestrant (ICI182780). End points included proliferation, cell signalling, cell cycle, and effect on ER-mediated transactivation. An in-vivo model of AI resistance was treated with monotherapies and combinations to assess the efficacy in delaying tumour progression. RNA-seq analysis was performed to identify changes in global gene expression as a result of the indicated therapies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Here, we show RAD001 and neratinib (pan-ERBB inhibitor) caused a concentration-dependent decrease in proliferation, irrespective of the <jats:italic>ESR1<\/jats:italic> mutation status. The combination of either agent with endocrine therapy further reduced proliferation but the maximum effect was observed with a triple combination of RAD001, neratinib, and endocrine therapy. In the absence of oestrogen, RAD001 caused a reduction in ER-mediated transcription in the majority of the cell lines, which associated with a decrease in recruitment of ER to an oestrogen-response element on the <jats:italic>TFF1<\/jats:italic> promoter. Contrastingly, neratinib increased both ER-mediated transactivation and ER recruitment, an effect reduced by the addition of RAD001. In-vivo analysis of an LTED model showed the triple combination of RAD001, neratinib, and fulvestrant was most effective at reducing tumour volume. Gene set enrichment analysis revealed that the addition of neratinib negated the epidermal growth factor (EGF)\/EGF receptor feedback loops associated with RAD001.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our data support the combination of therapies targeting ERBB2\/3 and mTORC1 signalling, together with fulvestrant, in patients who relapse on endocrine therapy and retain a functional ER.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13058-018-0983-1","type":"journal-article","created":{"date-parts":[[2018,6,4]],"date-time":"2018-06-04T08:11:39Z","timestamp":1528099899000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer"],"prefix":"10.1186","volume":"20","author":[{"given":"Ricardo","family":"Ribas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Pancholi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aradhana","family":"Rani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie K.","family":"Guest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Nikitorowicz-Buniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikiana","family":"Simigdala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Thornhill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Avogadri-Connors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Richard E.","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alshad S.","family":"Lalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitch","family":"Dowsett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7606-4161","authenticated-orcid":false,"given":"Lesley-Ann","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,8]]},"reference":[{"key":"983_CR1","doi-asserted-by":"crossref","unstructured":"Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast Cancer: Epidemiology and Etiology. Cell Biochem Biophys. 2015;72(2):333\u20138.","DOI":"10.1007\/s12013-014-0459-6"},{"issue":"8","key":"983_CR2","doi-asserted-by":"publisher","first-page":"772","DOI":"10.4161\/cbt.3.8.994","volume":"3","author":"KE Bachman","year":"2004","unstructured":"Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther. 2004;3(8):772\u20135.","journal-title":"Cancer Biol Ther"},{"issue":"5","key":"983_CR3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1530\/ERC-10-0046","volume":"18","author":"SC Drury","year":"2011","unstructured":"Drury SC, Detre S, Leary A, Salter J, Reis-Filho J, Barbashina V, Marchio C, Lopez-Knowles E, Ghazoui Z, Habben K, et al. Changes in breast cancer biomarkers in the IGF1R\/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocr Relat Cancer. 2011;18(5):565\u201377.","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"983_CR4","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/annonc\/mdt575","volume":"25","author":"M Arnedos","year":"2014","unstructured":"Arnedos M, Drury S, Afentakis M, A'Hern R, Hills M, Salter J, Smith IE, Reis-Filho JS, Dowsett M. Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. Ann Oncol. 2014;25(3):605\u201310.","journal-title":"Ann Oncol"},{"issue":"5","key":"983_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrc3920","volume":"15","author":"CX Ma","year":"2015","unstructured":"Ma CX, Reinert T, Chmielewska I, Ellis MJ. Mechanisms of aromatase inhibitor resistance. Nat Rev Cancer. 2015;15(5):261\u201375.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"983_CR6","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.mce.2013.09.038","volume":"382","author":"N Patani","year":"2014","unstructured":"Patani N, Martin LA. Understanding response and resistance to oestrogen deprivation in ER-positive breast cancer. Mol Cell Endocrinol. 2014;382(1):683\u201394.","journal-title":"Mol Cell Endocrinol"},{"issue":"6","key":"983_CR7","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520\u20139.","journal-title":"N Engl J Med"},{"issue":"3","key":"983_CR8","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","volume":"66","author":"KE O'Reilly","year":"2006","unstructured":"O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66(3):1500\u20138.","journal-title":"Cancer Res"},{"issue":"5","key":"983_CR9","doi-asserted-by":"publisher","first-page":"R132","DOI":"10.1186\/bcr3330","volume":"14","author":"LA Martin","year":"2012","unstructured":"Martin LA, Pancholi S, Farmer I, Guest S, Ribas R, Weigel MT, Thornhill AM, Ghazoui Z, A'Hern R, Evans DB, et al. Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo. Breast Cancer Res. 2012;14(5):R132.","journal-title":"Breast Cancer Res"},{"issue":"9","key":"983_CR10","first-page":"3065","volume":"118","author":"A Carracedo","year":"2008","unstructured":"Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008;118(9):3065\u201374.","journal-title":"J Clin Invest"},{"issue":"8","key":"983_CR11","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.2009.25.8707","volume":"28","author":"HJ Burstein","year":"2010","unstructured":"Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, Awada A, Ranade A, Jiao S, Schwartz G, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2010;28(8):1301\u20137.","journal-title":"J Clin Oncol"},{"issue":"18","key":"983_CR12","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1200\/JCO.2009.27.9414","volume":"28","author":"LV Sequist","year":"2010","unstructured":"Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton K, Zacharchuk C, Freyman A, Powell C, et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(18):3076\u201383.","journal-title":"J Clin Oncol"},{"issue":"15","key":"983_CR13","doi-asserted-by":"publisher","first-page":"5934","DOI":"10.18632\/oncotarget.1904","volume":"5","author":"SN Mohd Nafi","year":"2014","unstructured":"Mohd Nafi SN, Generali D, Kramer-Marek G, Gijsen M, Strina C, Cappelletti M, Andreis D, Haider S, Li JL, Bridges E, et al. Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget. 2014;5(15):5934\u201349.","journal-title":"Oncotarget"},{"issue":"5","key":"983_CR14","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1186\/s13058-014-0447-1","volume":"16","author":"R Ribas","year":"2014","unstructured":"Ribas R, Ghazoui Z, Gao Q, Pancholi S, Rani A, Dunbier A, Dowsett M, Martin LA. Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers. Breast Cancer Res. 2014;16(5):447.","journal-title":"Breast Cancer Res"},{"issue":"3","key":"983_CR15","doi-asserted-by":"publisher","first-page":"R78","DOI":"10.1186\/bcr3191","volume":"14","author":"MT Weigel","year":"2012","unstructured":"Weigel MT, Ghazoui Z, Dunbier A, Pancholi S, Dowsett M, Martin LA. Preclinical and clinical studies of estrogen deprivation support the PDGF\/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer. Breast Cancer Res. 2012;14(3):R78.","journal-title":"Breast Cancer Res"},{"issue":"33","key":"983_CR16","doi-asserted-by":"publisher","first-page":"30458","DOI":"10.1074\/jbc.M305226200","volume":"278","author":"LA Martin","year":"2003","unstructured":"Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem. 2003;278(33):30458\u201368.","journal-title":"J Biol Chem"},{"issue":"7","key":"983_CR17","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1200\/JCO.2007.12.9437","volume":"26","author":"M Dowsett","year":"2008","unstructured":"Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol. 2008;26(7):1059\u201365.","journal-title":"J Clin Oncol"},{"issue":"5","key":"983_CR18","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nbt.1621","volume":"28","author":"C Trapnell","year":"2010","unstructured":"Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ, Pachter L. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28(5):511\u20135.","journal-title":"Nat Biotechnol"},{"issue":"14","key":"983_CR19","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1093\/bioinformatics\/btt285","volume":"29","author":"W Luo","year":"2013","unstructured":"Luo W, Brouwer C. Pathview: an R\/Bioconductor package for pathway-based data integration and visualization. Bioinformatics. 2013;29(14):1830\u20131.","journal-title":"Bioinformatics"},{"issue":"43","key":"983_CR20","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"983_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13058-016-0713-5","volume":"18","author":"N Simigdala","year":"2016","unstructured":"Simigdala N, Gao Q, Pancholi S, Roberg-Larsen H, Zvelebil M, Ribas R, Folkerd E, Thompson A, Bhamra A, Dowsett M, et al. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer. Breast Cancer Res. 2016;18(1):58.","journal-title":"Breast Cancer Res"},{"issue":"4","key":"983_CR22","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/febs.13172","volume":"282","author":"T Nagashima","year":"2015","unstructured":"Nagashima T, Inoue N, Yumoto N, Saeki Y, Magi S, Volinsky N, Sorkin A, Kholodenko BN, Okada-Hatakeyama M. Feedforward regulation of mRNA stability by prolonged extracellular signal-regulated kinase activity. FEBS J. 2015;282(4):613\u201329.","journal-title":"FEBS J"},{"issue":"13","key":"983_CR23","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1158\/1078-0432.CCR-13-2769","volume":"20","author":"NA O'Brien","year":"2014","unstructured":"O'Brien NA, McDonald K, Tong L, von Euw E, Kalous O, Conklin D, Hurvitz SA, di Tomaso E, Schnell C, Linnartz R, et al. Targeting PI3K\/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT. Clin Cancer Res. 2014;20(13):3507\u201320.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"983_CR24","doi-asserted-by":"publisher","first-page":"6730","DOI":"10.1158\/1078-0432.CCR-08-0581","volume":"14","author":"FL Chen","year":"2008","unstructured":"Chen FL, Xia W, Spector NL. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin Cancer Res. 2008;14(21):6730\u20134.","journal-title":"Clin Cancer Res"},{"issue":"25","key":"983_CR25","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1200\/JCO.2006.09.6578","volume":"25","author":"IE Smith","year":"2007","unstructured":"Smith IE, Walsh G, Skene A, Llombart A, Mayordomo JI, Detre S, Salter J, Clark E, Magill P, Dowsett M. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol. 2007;25(25):3816\u201322.","journal-title":"J Clin Oncol"},{"issue":"33","key":"983_CR26","doi-asserted-by":"publisher","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","volume":"27","author":"S Johnston","year":"2009","unstructured":"Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009;27(33):5538\u201346.","journal-title":"J Clin Oncol"},{"key":"983_CR27","doi-asserted-by":"crossref","unstructured":"Johnston S, Basik M, Hegg R, Lausoontornsiri W, Grzeda L, Clemons M, Dreosti L, Mann H, Stuart M, Cristofanilli M. Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-na\u00efve advanced breast cancer. Breast Cancer Res Treat. 2016;160(1):91\u201399.","DOI":"10.1007\/s10549-016-3979-5"},{"issue":"9","key":"983_CR28","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/jnci\/djk151","volume":"99","author":"G Arpino","year":"2007","unstructured":"Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, De Placido S, Osborne CK, Schiff R. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst. 2007;99(9):694\u2013705.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"983_CR29","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1158\/1078-0432.CCR-10-1869","volume":"17","author":"CK Osborne","year":"2011","unstructured":"Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, Migliaccio I, Anagnostou VK, et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res. 2011;17(5):1147\u201359.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"983_CR30","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/sj.onc.1203416","volume":"19","author":"SP Newman","year":"2000","unstructured":"Newman SP, Bates NP, Vernimmen D, Parker MG, Hurst HC. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene. 2000;19(4):490\u20137.","journal-title":"Oncogene"},{"key":"983_CR31","doi-asserted-by":"crossref","unstructured":"Hortobagyi GN, Chen D, Piccart M, Rugo HS, Burris HA 3rd, Pritchard KI, Campone M, Noguchi S, Perez AT, Deleu I, Shtivelband M, Masuda N, Dakhil S, Anderson I, Robinson DM, He W, Garg A, McDonald ER 3rd, Bitter H, Huang A, Taran T, Bachelot T, Lebrun F, Lebwohl D, Baselga J. Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. J Clin Oncol. 2016;34(5):419\u201326.","DOI":"10.1200\/JCO.2014.60.1971"},{"issue":"2","key":"983_CR32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1200\/JCO.2012.47.2787","volume":"32","author":"L Gandhi","year":"2014","unstructured":"Gandhi L, Bahleda R, Tolaney SM, Kwak EL, Cleary JM, Pandya SS, Hollebecque A, Abbas R, Ananthakrishnan R, Berkenblit A, et al. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol. 2014;32(2):68\u201375.","journal-title":"J Clin Oncol"},{"issue":"8","key":"983_CR33","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/sj.bjc.6605641","volume":"102","author":"AH Evans","year":"2010","unstructured":"Evans AH, Pancholi S, Farmer I, Thornhill A, Evans DB, Johnston SR, Dowsett M, Martin LA. EGFR\/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2\/ER-positive breast cancer cells but functions synergistically with endocrine therapy. Br J Cancer. 2010;102(8):1235\u201343.","journal-title":"Br J Cancer"}],"updated-by":[{"DOI":"10.1186\/s13058-025-02046-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000}}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-018-0983-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-018-0983-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-018-0983-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T02:50:38Z","timestamp":1750733438000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-018-0983-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,8]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["983"],"URL":"https:\/\/doi.org\/10.1186\/s13058-018-0983-1","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,8]]},"assertion":[{"value":"22 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13058-025-02046-1","URL":"https:\/\/doi.org\/10.1186\/s13058-025-02046-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In-vivo studies were carried out in accordance with Home Office guidelines and approved by the Institute of Cancer Research Ethics Committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the final version of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"L-AM and SRJ receive academic funding from PUMA Biotechnology. FA-C, ASL, and REC are employees of PUMA Biotechnology. The remaining authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"44"}}